Medtronic plc超过收入预测, 计划增长, 并计划从糖尿病业务中解脱出来。 Medtronic plc surpassed earnings forecasts, projects growth, and plans to spin off its Diabetes business.

医疗设备公司Medtronic plc在第四季度比收入估计数高出1%,并报告利润增加1%。 Medical device company Medtronic plc beat earnings estimates in the fourth quarter and reported a 1% increase in profit. 在2026财政年度,Medtronic项目收入在每股5.50至5.60美元之间,预计收入增长4.8%至5.1%。 For fiscal year 2026, Medtronic projects earnings between $5.50 and $5.60 per share, with revenue growth expected at 4.8 to 5.1%. 该公司还计划在18个月内将其糖尿病业务分离为一家独立的公营公司,可能通过IPO和分解。 The company also plans to separate its Diabetes business into a standalone public company within 18 months, likely through an IPO and split-off.